Lilly Evista Breast Cancer Market May Build On Osteo Acceptance
Executive Summary
Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer
You may also be interested in...
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial
Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling